Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Call you Congressmen about Farm Bill! Tell them how important it is for farmers for them to pass it by End of Year!
Find the phone numbers of the congressmen for your area here:
Click Here
A Thomas Jefferson quote that you never heard before.
"Hemp is of first necessity to the wealth and protection of the country." --Thomas Jefferson
Trevor Moore: Drunk Texts to Myself - "Founding Fathers" - Uncensored
Thomas Jefferson quote you didn't know about:
"Hemp is of first necessity to the wealth and protection of the country." --Thomas Jefferson
"Hemp is of first necessity to the wealth and protection of the country." --Thomas Jefferson
Trevor Moore: Drunk Texts to Myself - "Founding Fathers" - Uncensored
Coca Cola wants in on the CBD green rush. Pepsi and Starbucks will most likely follow to remain competitive.
Coca-Cola Dipping Into the Cannabis Infused Drink Market
Earnings/Farm Bill/NASDAQ/Coca-Cola/Pepsi/Starbucks.. Those are just a few of the pending catalysts. Need I say more?
Plus CBD is legal. See here:
My post from earlier in case you missed it.
Why CVSI is not breaking the Law
In an attempt to unravel this master jigsaw puzzle surrounding the recent DEA order to re-schedule Epidiolex, I present to you the laws that currently stand on the books. This information is worth gold in my opinion.
Problem:
Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol
"As further indicated, any material, compound, mixture, or preparation other than Epidiolex that falls within the CSA definition of marijuana set forth in 21 U.S.C. 802(16), including any non-FDA-approved CBD extract that falls within such definition, remains a schedule I controlled substance under the CSA. Thus, persons who handle such items will continue to be subject to the requirements of the CSA and DEA regulations relating to schedule I controlled substances."
----------------------------------------------------------------------------
Solution 1:
Hemp Industries Association Reaches Settlement with DEA and Affirms Victory from 2004 Hemp Foods Rules Challenge
“We are grateful to our counsel for successfully negotiating the necessary clarification in this matter and we will remain the first line of defense to ensure the undisrupted continuance of the hemp industries as we bring new economic opportunities to farmers and entrepreneurs, and also healthy U.S. made food products to the American marketplace and eventually around the world.”
"As for the legality of CBD, Syed says its status in the U.S. will be determined “in a court of law.” “Hemp and hemp extracts are federally legal,” she says. “The debate, however, around exactly how FDA will view isolated cannabidiol (CBD) will on only be determined in the court of law.” She notes that CV Sciences’ PlusCBD Oil products, which are sold in health food stores nationwide, are made from “lawfully imported” industrial hemp."
"In terms of notable challenges formulating CBD into a gummy, typical hurdles included taste—especially when working with a full-spectrum product like PlusCBD, which utilizes the whole hemp plant and therefore inevitably has the notable flavor and odor of hemp. “Because we use the seed, the stem, and the stalk, we do get this noted taste we believe is coming from the hemp seeds and the shells themselves and even the waxes and longer-chain saturated fats that are in the stem and stock,” explains Tomc. By using its Gold line of hemp-derived CBD, however, CV Sciences started with the most distilled and concentrated version of its product, compared to its Red and Green lines, which are rawer."
"This past June, the Food and Drug Administration (FDA) issued its long-expected approval of GW Pharmaceutical’s Epidiolex, a cannabidiol (CBD) oral solution for certain acute medical conditions. (Read more about it here.)
As a consequence of the FDA’s action, the Drug Enforcement Administration (DEA) today re-scheduled Epidiolex, and any future FDA-approved CBD drug, under Schedule V of the Controlled Substances Act. Read the full unpublished order here.
Concerns about how hemp-derived CBD products might be treated in this context prompted the US Hemp Roundtable to hire the law firm of Amin Talati Upadhye to counsel on FDA-related issues. Here is their analysis of today’s DEA order:
--Today the DEA announced that Epiodiolex, a highly purified, pharmaceutical firm of CBD, will be placed under schedule V of the Controlled Substances Act. In doing so, DEA noted that the drug no longer meets the criteria for schedule I, following FDA’s approval of the drug for certain medical conditions. DEA also indicated that any material, compound, mixture, or preparation other than Epidiolex that falls within the CSA definition of marijuana set forth in 21 U.S.C. 802(16), including any non-FDA-approved CBD extract that falls within such definition, remains a schedule I controlled substance under the CSA.
--The placement of Epidiolex under schedule V – the least restrictive schedule – recognizes the proven health benefits of CBD and its low potential for abuse. Of note, DEA’s scheduling determination is limited to only Epidiolex and generic versions of the same formulation. Therefore it is our opinion that DEA’s announcement and related statements have no bearing on the status of hemp-derived CBD.""
How do you make a cannabis derivative like Epidiolex schedule V without removing marijuana, its source, from schedule I —considering that schedule I means that the plant has no known medical uses??? Hmmmmmm. —Sounds like grounds to sue the DEA again. —Just a thought.
FDA: CBD has a negligible abuse potential.
I. Abuse potential
The Controlled Substances Staff evaluated the abuse potential of cannabidiol in nonclinical studies and in a human abuse potential study, and has concluded that CBD has a negligible abuse potential. Please refer to the consultation memo from the Controlled Substances Staff in Section IV for a more detailed discussion of the assessment of abuse potential.
Therefore, an overall assessment of the abuse-related data from preclinical and clinical studies leads to the finding that CBD has negligible abuse potential.
What makes me excited about NASDAQ and the Farm Bill? --Institutional and risk-averse investors hopping on-board. The company will still do well without them, but it will be a huge bonus if either of those are achieved.
NASDAQ uplisting isn't dependent on the Farm Bill; it's dependent on the exchange's opinion. CVSI imports their hemp from Europe, and the US has been importing hemp for years and processing it. The DEA was recently sued, and they confirmed that hemp products are legal. The FDA, in a briefing based on clinical trials from GW Pharma, stated that CBD has negligible abuse potential; however, they didn't say that Epidiolex has negligible abuse potential; I repeat, they said CBD has negligible abuse potential, which makes its schedule 1 status UNTENABLE. See it in the link below. I feel that CVSI is likely to pass the NASDAQ test whether we get a Farm Bill or not this year, which would also, like the Farm Bill, open up the flood gates to institutional investors. I don't have much concern here whatsoever. Also, the Farm Bill must pass to help struggling farmers, and if it doesn't, then 2019 it is, and the farmers will just have to struggle for another year thanks to inaction in Congress, but I don't think anyone wants that. CVSI is an amazing company with Godlike financials, and I believe it will be a titan in the industry in the future. I am holding Long Term, and I plan to do so for maybe 10 years or longer. At that point, we'll probably be looking at nice dividend payouts to shareholders once sales eventually plateau. With only 5% market penetration in the mega US market (20X the size of Canada's), there is still plenty of room to grow. I expect 40X growth of CVSI (minimum) within the next 4 years.
FDA Briefing Document on CBD
My analysis if the Farm Bill doesn't pass this year.
See it by CLICKING here
I think we have a real winner here. --A true Grand Master of the stock market world. A Citigroup-trained CEO. An NFL top neurosurgeon. A looming Farm Bill with a hemp legalization provision attached. A top investment publication company's support. An imminent Nasdaq uplisting. No debt. A legal product --confirmed by the DEA after they were sued. A lawsuit with no merit. A profitable company with consistently increasing revenues. Gigantic companies looking for top CBD players. Entered the CBD space prior to GW Pharma's investigational new drug consideration of Epidiolex, which makes CVSI's product legal since it was considered a drug supplement FIRST, which qualifies their product for the exception in their CBD rules since the product is an imported product of hemp. Market penetration of only 5%. Baby boomers getting old. A market 20X the size of Canada. An industry expected to grow 40X. Institutional investors soon to hop on board after Farm Bill passage. Risk averse investors soon to jump on board. A strong retail presence including a listing on Amazon. Great targeted Ad placements on top news websites. A product that actually works and isn't just a sugar pill. High market manipulation allowing the Big Wigs to keep the price low for the time being. Amazing consumer sentiment. I know I missed a lot of perks. There is nothing at all that will stop this from going to the grand central sun of the universe. All invested at this time will be able to tell their grand children about the stock that allowed them to have the comfortable existence that they do in this short life. My grandfather was a high king of Ireland, and he would be proud of my stock choice.
CIIX is sitting on 3 million cash. They will greatly benefit from their dealings in BC and China. --And America. The CEO is conservatively professional and doesn't rely on junk pr to pump up the stock. The Farm Bill will pass eventually, and when it does, we're good here. We're heading to the grand central sun of the universe here, and there is absolutely nothing that anyone is going to do about it.
So, who's going to come with me on my yacht?
I still love you my HIPH! Check out the boards over at CVSI for recent revelations regarding hemp-derived CBD. Very good knowledge that is highly relevant for my baby right here!
You have to realize that the bipartisan STATES Act is just around the corner. That would make cannabis federally legal in any state that chooses to do so. That would ease the barriers currently holding LBUY back. Sen. Dianne Feinstein just signed on as a cosponsor, and more cosponsors were added on the house side too. LBUY is going to Mars soon and ain't ever coming back down this time!
You have to realize that the *bipartisan* STATES Act is just around the corner. That would make cannabis federally legal in any state that chooses to do so. That would ease the barriers currently holding MSRT back. Sen. Dianne Feinstein just signed on as a cosponsor, and more cosponsors were added on the house side too. MSRT is going to pop soon!
STATES Act Cosponsors
Why would Pepsi look at TLRY when CVSI is much more undervalued, has a stronger balance sheet, has a Farm Bill looming that will legalize hemp, and a market cap of just $500 million? That's a huge discount! Plus, the NFL's top neurosurgeon has signed on to work with them, and he bought a lot of shares. I think you guys need to do your DD there.
Treason committed by DEA and FDA!!!
Hey FDA! I'm sure you're watching and reading since your credibility is on the line. I'm just going to point out that the American people are not very happy with your scandalous ways, and I would advise you to do the right thing and advocate for the complete descheduling of cannabis. Anything else will be considered sub-par. The DEA should do the same unless you want to become agencies of the past due to treason against the American people by denying them medicine that you knew was medicine. For example, the Medical College of Virginia in 1974 with a study showed that mice and rats' tumors were shrinking after they were exposed to THC. Why did you scrap this study? My family members died of cancer because of your negligence, and now, my words are payback for that.
What Your Government Knows About Cannabis And Cancer — And Isn’t Telling You
Right, I forgot to mention the patent. The FDA and DEA have dug their own grave and nailed their own coffins. They are next in the swamp-drain phase if there is any truth to Trump's statements regarding draining the swamp.
Cannabis has an untenable schedule I status.
See here why.
Source:
FDA Briefing Document on CBD
"Based on clinical experimental data, CBD does not appear to have abuse potential:
• In a Phase 1 human abuse potential study with CBD, there were some slight abuse-related signals from the positive subjective measures, but these responses were close to being within the acceptable placebo range and were much lower than the abuse-related signals produced by the positive control drugs with known abuse potential (dronabinol and alprazolam). CBD produced a low level of euphoria-related adverse events (AEs), but this was much lower than that produced by dronabinol and did not predict positive subjective responses.
• There were no euphoria-related AEs in other Phase 1 clinical studies conducted with CBD in a non-patient population that would be indicative of abuse potential. Drugs that have abuse potential typically produce euphoria-related AEs in clinical studies. Phase 2 clinical studies with CBD were not assessed for euphoria related AEs because the antiepileptic medication patients were also taking can have known abuse potential that would confound the evaluation.
55
CSS Background Document
Cannabidiol NDA 210,365
Therefore, an overall assessment of the abuse-related data from preclinical and clinical studies leads to the finding that CBD has negligible abuse potential."
"This is the list of Schedule I drugs as defined by the United States Controlled Substances Act.[1] The following findings are required for drugs to be placed in this schedule:[2]
1. The drug or other substance has a high potential for abuse.
2. The drug or other substance has no currently accepted medical use in treatment in the United States.
3. There is a lack of accepted safety for use of the drug or other substance under medical supervision."
Now this is some impressive DD. Great work my friend.
What's really going to get ya is that Epidiolex has not been scheduled at all. Check this Chronological list of the DEA's list of controlled substances:
DEA Chronological Controlled Substances List
Oh, believe me, the squeeze is coming.
I mean, they are both cannabis, but they are completely different strains. Hemp is grown with males and females which reduces THC content due to pollination. Industrial hemp is also a low-THC strain in general. Hemp is cannabis that has less than .03% THC, but it's still cannabis. It's all cannabis. I wouldn't necessarily call them different plants entirely though, because that would be a stretch. Medical marijuana is grown in individual pots, and the males are removed. Hemp is sown very closely together which causes it to grow fibrous and tall as it competes with its closely sown neighbors towards the light. The moment medical cannabis gets pollinated by males, the crop gets ruined due to lower THC and high seed content. --That's what some people call "Reggie." One thing is clear though, the crops are extremely distinguishable. You can tell which ones are grown for fiber and which ones are grown for medicine.
Google FDA and DEA Scandals. Be scared.
Can a man get a sticky on this?
But you have to consider the source of the CBD. CVSI sources it from hemp which is imported from outside the country. CVSI is playing their cards right. Shorts are going to get squeezed.
Question on FDA "available evidence."
FDA and Marijuana: Questions and Answers
There is an exception to sections 201(ff)(3)(B)(i) and (ii) if the substance was "marketed as" a dietary supplement or as a conventional food before the drug was approved or before the new drug investigations were authorized, as applicable. However, based on available evidence, FDA has concluded that this is not the case for THC or CBD. For more information on this provision, including an explanation of the phrase "marketed as," see Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues.
Can CBD products be sold as dietary supplements? I have the answer.
Problem Source 1:
CV Sciences ventures into food space following CBD safety assessment
"FDA has asserted CBD can’t be sold in foods or supplements. Its reasoning is tied to clinical investigations instituted by GW Pharmaceuticals plc, which obtained FDA approval in June to market Epidiolex, a CBD drug to treat seizures associated with certain forms of epilepsy."
"FDA has asserted CBD can’t be sold in foods or supplements. Its reasoning is tied to clinical investigations instituted by GW Pharmaceuticals plc, which obtained FDA approval in June to market Epidiolex, a CBD drug to treat seizures associated with certain forms of epilepsy."
“Self-affirmed GRAS status also doesn’t change the fact that the FDA still considers CBD to be a nonpermissible ingredient due to the investigation of a new drug,” Prochnow, a partner with Greenberg Traurig LLP, wrote in an email. “However, if the ingredient investigated by GW Pharma is sufficiently distinguished, it does pave the way for strong arguments about its use in foods and beverages.”
“Is there a lawful basis to market it—a standardized CBD product—in light of GW Pharma?” the regulatory lawyer asked. “It could be the safest ingredient in the whole world. It doesn’t matter.”
"12. Can products that contain THC or cannabidiol (CBD) be sold as dietary supplements?
A. No. Based on available evidence, FDA has concluded that THC and CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, respectively. Under those provisions, if a substance (such as THC or CBD) is an active ingredient in a drug product that has been approved under 21 U.S.C. § 355 (section 505 of the FD&C Act), or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. FDA considers a substance to be "authorized for investigation as a new drug" if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under FDA’s regulations (21 CFR 312.2), unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.
There is an exception to sections 201(ff)(3)(B)(i) and (ii) if the substance was "marketed as" a dietary supplement or as a conventional food before the drug was approved or before the new drug investigations were authorized, as applicable. However, based on available evidence, FDA has concluded that this is not the case for THC or CBD. For more information on this provision, including an explanation of the phrase "marketed as," see Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues.
FDA is not aware of any evidence that would call into question its current conclusions that THC and CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act. Interested parties may present the agency with any evidence that they think has bearing on this issue. Our continuing review of information that has been submitted thus far has not called our conclusions into question."
"12. May I manufacture and sell a dietary supplement containing a dietary ingredient that was marketed as a food or dietary supplement before it was approved as a drug, licensed as a biologic, or authorized for investigation under an IND?
Yes, in this situation the dietary ingredient may be used in dietary supplements. In considering whether a substance has been “marketed as a dietary supplement or as a food,” FDA looks for evidence of one of the following:
1. Evidence that the substance itself was sold or offered for sale in the U.S. as a dietary supplement, dietary ingredient for use in dietary supplements, or conventional food. For example, a catalog listing a product identified as a “Substance A supplement” would establish the marketing of Substance A as a dietary supplement. Similarly, business records documenting that a substance was sold or offered for wholesale or retail sale for use as an ingredient in a conventional food would establish the marketing of the substance as a food.
2. Evidence that the substance was a component of a food or dietary supplement that was sold or offered for sale in the U.S., and that a manufacturer or distributor of the food or dietary supplement marketed it for the content of the substance by, for example, making claims about the substance or otherwise highlighting its presence in the product. For example, in Pharmanex v. Shalala, the firm marketed lovastatin, a component of its red yeast rice product Cholestin, by promoting the lovastatin content of Cholestin. Merely showing that the substance was present as a component in a marketed food would not be enough to show that the substance was “marketed,” however."
"FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required."
"Expressing a view that he said is “broadly shared by the marketplace,” Tomc said hemp-derived CBD was marketed before any “substantial clinical investigations” began and were publicized."
“The investigations that were publicized were not substantial, due to being limited in number and preliminary in nature, thereby rendering the IND [investigational new drug] preclusion inapplicable,” he added. “Furthermore, the IND preclusion isn’t a new conversation in the dietary supplement industry. Many ingredients such as trans-resveratrol, P5P [pyridoxal-5-phosphate] and DHEA [dehydroepiandrosterone] have been subject to the same scrutiny and continue to be sold as dietary supplements.”
"A national group, Hemp Industries Association, sued the DEA over its scheduling of CBD. The two have since mediated the case, resulting in the DEA issuing an internal directive in May that re-emphasized the legality of hemp products, according to HIA."
"HEMP.—The term ‘hemp’ means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."
"SEC. 12608. CONFORMING CHANGES TO CONTROLLED SUBSTANCES ACT.
(a) In General.—Section 102(16) of the Controlled Substances Act (21 U.S.C. 802(16)) is amended—
(1) by striking “(16) The” and inserting “(16)(A) Subject to subparagraph (B), the”; and
(2) by striking “Such term does not include the” and inserting the following:
“(B) The term ‘marihuana’ does not include—
“(i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946; or
“(ii) the”.
(b) Tetrahydrocannabinol.—Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)), is amended in subsection (c)(17) by inserting after “Tetrahydrocannabinols” the following: “, except for tetrahydrocannabinols in hemp (as defined under section 297A of the Agricultural Marketing Act of 1946)”."
"SEC. 10112. RULE OF CONSTRUCTION.
Nothing in this title authorizes interference with the interstate commerce of hemp (as defined in section 297A of the Agricultural Marketing Act of 1946, as added by section 10111)."
Considering that CVSI has no debt, I expect those earnings to be at a bare minimum .05 per share compared to the current .03 per share assuming that no major investments take away from that.
Prove it.
The best thing to do is find places with the most traffic to spread the word.
People must know that this stock exists and that the lawsuits are meritless. They must know that the Farm Bill will lead to exponential growth for CVSI. Institutional investors can't touch CVSI right now, and risk averse investors won't touch it; however, the Farm Bill's passage will lead to a gigantic pop-to-the-top in the stock when billionaire institutional investors get the green light and when risk averse investors invest as a result of feeling less risk.
Imagine if the patent passed, opening up new market opportunities.
Imagine if the balance sheet went up from .03 EPS to .08 EPS, what would that do if the stock maintained approximately its same PE ratio?
What would happen if CVSI wins the lawsuit? My sticky post should give them all the ammo that they need to win.
What will happen with a NASDAQ uplisting?
What if CVSI strikes a major deal with a $100+ billion dollar company?
What will happen with passage of the States Act?
What will happen with the passage of the Marijuana Justice Act?
What if people knew that the industry would multiply around 40 times by 2022 according to this?
Most people are clueless about this company still, but spreading the word to high traffic places is key to spreading the word and changing your destiny. Have at it troops!
PS: I'm sure that there are more catalysts to consider; those are just the few off of the top of my head.
I'm deeply invested in CVSI. Long and Strong all the way to $100 per share.
L+S on HIPH. They need to show revenues after the release of their new CBD water product in order to establish a better base. I suppose they may drop a bit, where I would buy more shares, since they are up on hype right now, but one good balance sheet release could send them to .15 or above.
I dont deny that there is a large prison labor force out there, but if the Farm Bill passes and a lot less people go to prison for drug offenses, I am willing to bet there is still a large population inside the prison walls to draw from. I dont see that being much of an issue myself.
Prove that Mona's still calling the shots.
What's the source of the NY trip?